Henan Cancer Hospital
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
Axillary Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Patients With Initial cN1 Breast Cancer
- First Posted Date
- 2024-07-24
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 508
- Registration Number
- NCT06518135
- Locations
- 🇨🇳
Henan cacer hospital, Henan, Henan, China
Backline Treatment of Advanced Hepatocellular Carcinoma With Palbociclib
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT06478927
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
L218CAR19 in Patients With Relapsed/Refractory B-cell Lymphoma
- First Posted Date
- 2024-06-27
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 22
- Registration Number
- NCT06478381
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, China
Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCs
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-26
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT06475443
Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC
- First Posted Date
- 2024-06-18
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 30
- Registration Number
- NCT06465238
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-06-12
- Last Posted Date
- 2024-06-12
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT06454890
An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung Cancer
- First Posted Date
- 2024-05-31
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 39
- Registration Number
- NCT06436885
- Locations
- 🇨🇳
Henan cancer hospital, Zhengzhou, Henan, China
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-23
- Last Posted Date
- 2024-05-23
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 41
- Registration Number
- NCT06427213
Patient-derived Organoid Drug Sensitivity Guided Treatment for Drug-resistant Recurrent Non-Small Cell Lung Cancer
Not Applicable
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 20
- Registration Number
- NCT06406608
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung Cancer
Phase 2
Recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-05-09
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 70
- Registration Number
- NCT06406673
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
© Copyright 2024. All Rights Reserved by MedPath